KDM5C
KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
Overview
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Everolimus, Capivasertib and Sunitinib. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.98, animal model 0.44, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 10 cohorts (1 activating, 9 loss-of-function), covering Renal Clear Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma, Plasma Cell Myeloma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
- 1 · What it is
KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
- 2 · What goes wrong in cancer
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'.
- 3 · How drugs use it
No product in this corpus aims at KDM5C yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11114 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P41229 (protein name, function text, keywords and locations (REST API)); CIViC gene KDM5C (2 evidence items, 0 assertions, 2 variants; diseases: Oestrogen Receptor-positive Breast Cancer, Renal Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000126012 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.53, renal cell carcinoma 0.68, skin cancer 0.54 (GraphQL API, CC0)); IntOGen KDM5C (driver in 10 cohorts (Act 1, LoF 9); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Location: Nucleus (UniProt). Locus Xp11.22 (HGNC).
- Renal cell carcinoma: Open Targets association 0.68 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 9 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KDM5C" OR ABSTRACT:"KDM5C" OR TITLE:"lysine demethylase 5C" OR ABSTRACT:"lysine demethylase 5C" OR TITLE:"Lysine-specific demethylase 5C" OR ABSTRACT:"Lysine-specific demethylase 5C" OR TITLE:"DXS1272E" OR ABSTRACT:"DXS1272E" OR TITLE:"XE169" OR ABSTRACT:"XE169" OR TITLE:"JARID1C" OR ABSTRACT:"JARID1C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KDM5C, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetATG7
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
- TargetCHD4
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetPTPRK
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetARHGEF12
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetRANBP2
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetRAP1GDS1
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetARHGEF10L
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetMSN
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.